Cargando…

Host-Based Treatments for Severe COVID-19

COVID-19 has been a global health problem since 2020. There are different spectrums of manifestation of this disease, ranging from asymptomatic to extremely severe forms requiring admission to intensive care units and life-support therapies, mainly due to severe pneumonia. The progressive understand...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondini, Lucrezia, Salton, Francesco, Trotta, Liliana, Bozzi, Chiara, Pozzan, Riccardo, Barbieri, Mariangela, Tavano, Stefano, Lerda, Selene, Hughes, Michael, Confalonieri, Marco, Confalonieri, Paola, Ruaro, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136924/
https://www.ncbi.nlm.nih.gov/pubmed/37185727
http://dx.doi.org/10.3390/cimb45040203
_version_ 1785032336171073536
author Mondini, Lucrezia
Salton, Francesco
Trotta, Liliana
Bozzi, Chiara
Pozzan, Riccardo
Barbieri, Mariangela
Tavano, Stefano
Lerda, Selene
Hughes, Michael
Confalonieri, Marco
Confalonieri, Paola
Ruaro, Barbara
author_facet Mondini, Lucrezia
Salton, Francesco
Trotta, Liliana
Bozzi, Chiara
Pozzan, Riccardo
Barbieri, Mariangela
Tavano, Stefano
Lerda, Selene
Hughes, Michael
Confalonieri, Marco
Confalonieri, Paola
Ruaro, Barbara
author_sort Mondini, Lucrezia
collection PubMed
description COVID-19 has been a global health problem since 2020. There are different spectrums of manifestation of this disease, ranging from asymptomatic to extremely severe forms requiring admission to intensive care units and life-support therapies, mainly due to severe pneumonia. The progressive understanding of this disease has allowed researchers and clinicians to implement different therapeutic alternatives, depending on both the severity of clinical involvement and the causative molecular mechanism that has been progressively explored. In this review, we analysed the main therapeutic options available to date based on modulating the host inflammatory response to SARS-CoV-2 infection in patients with severe and critical illness. Although current guidelines are moving toward a personalised treatment approach titrated on the timing of presentation, disease severity, and laboratory parameters, future research is needed to identify additional biomarkers that can anticipate the disease course and guide targeted interventions on an individual basis.
format Online
Article
Text
id pubmed-10136924
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101369242023-04-28 Host-Based Treatments for Severe COVID-19 Mondini, Lucrezia Salton, Francesco Trotta, Liliana Bozzi, Chiara Pozzan, Riccardo Barbieri, Mariangela Tavano, Stefano Lerda, Selene Hughes, Michael Confalonieri, Marco Confalonieri, Paola Ruaro, Barbara Curr Issues Mol Biol Review COVID-19 has been a global health problem since 2020. There are different spectrums of manifestation of this disease, ranging from asymptomatic to extremely severe forms requiring admission to intensive care units and life-support therapies, mainly due to severe pneumonia. The progressive understanding of this disease has allowed researchers and clinicians to implement different therapeutic alternatives, depending on both the severity of clinical involvement and the causative molecular mechanism that has been progressively explored. In this review, we analysed the main therapeutic options available to date based on modulating the host inflammatory response to SARS-CoV-2 infection in patients with severe and critical illness. Although current guidelines are moving toward a personalised treatment approach titrated on the timing of presentation, disease severity, and laboratory parameters, future research is needed to identify additional biomarkers that can anticipate the disease course and guide targeted interventions on an individual basis. MDPI 2023-04-05 /pmc/articles/PMC10136924/ /pubmed/37185727 http://dx.doi.org/10.3390/cimb45040203 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mondini, Lucrezia
Salton, Francesco
Trotta, Liliana
Bozzi, Chiara
Pozzan, Riccardo
Barbieri, Mariangela
Tavano, Stefano
Lerda, Selene
Hughes, Michael
Confalonieri, Marco
Confalonieri, Paola
Ruaro, Barbara
Host-Based Treatments for Severe COVID-19
title Host-Based Treatments for Severe COVID-19
title_full Host-Based Treatments for Severe COVID-19
title_fullStr Host-Based Treatments for Severe COVID-19
title_full_unstemmed Host-Based Treatments for Severe COVID-19
title_short Host-Based Treatments for Severe COVID-19
title_sort host-based treatments for severe covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136924/
https://www.ncbi.nlm.nih.gov/pubmed/37185727
http://dx.doi.org/10.3390/cimb45040203
work_keys_str_mv AT mondinilucrezia hostbasedtreatmentsforseverecovid19
AT saltonfrancesco hostbasedtreatmentsforseverecovid19
AT trottaliliana hostbasedtreatmentsforseverecovid19
AT bozzichiara hostbasedtreatmentsforseverecovid19
AT pozzanriccardo hostbasedtreatmentsforseverecovid19
AT barbierimariangela hostbasedtreatmentsforseverecovid19
AT tavanostefano hostbasedtreatmentsforseverecovid19
AT lerdaselene hostbasedtreatmentsforseverecovid19
AT hughesmichael hostbasedtreatmentsforseverecovid19
AT confalonierimarco hostbasedtreatmentsforseverecovid19
AT confalonieripaola hostbasedtreatmentsforseverecovid19
AT ruarobarbara hostbasedtreatmentsforseverecovid19